Pathstone Family Office, LLC Ascendis Pharma A/S Transaction History

Pathstone Family Office, LLC

  • $15.6 Billion
  • Q3 2023

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Oct 23, 2023
SELL
$99.42 - $131.97 $2,187 - $2,903
-22 Reduced 0.97%
2,242 $273,000
Q4 2022

Feb 13, 2023
SELL
$99.42 - $131.97 $2,187 - $2,903
-22 Reduced 0.97%
2,242 $273,000
Q3 2022

Oct 23, 2023
BUY
$84.03 - $110.23 $190,243 - $249,560
2,264 New
2,264 $233,000
Q3 2022

Nov 14, 2022
BUY
$84.03 - $110.23 $190,243 - $249,560
2,264 New
2,264 $234,000
Q1 2021

May 14, 2021
SELL
$124.92 - $173.33 $8,744 - $12,133
-70 Closed
0 $0
Q3 2020

Nov 12, 2020
BUY
$134.29 - $154.32 $9,400 - $10,802
70 New
70 $11,000

Others Institutions Holding ASND

# of Institutions
244
Shares Held
58.8M
Call Options Held
250K
Put Options Held
377K
View Full List

About Ascendis Pharma A/S

ASND Quotes by TradingView
  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email